SOX2 and ovarian carcinoma: Yang et al., analyzed SOX-2 expression in clinical tissue samples and ovarian cancer cell lines using immunohistochemistry and real-time PCR and demonstrated that SOX-2 was overexpressed in paclitaxel-resistant cells [30].